Company research
CORCEPT THERAPEUTICS INC
CIK 1088856Updated Sep 26, 2026
SecurityCORT · NASDAQ · equity
CORT price & chart
Loading TradingView…
NASDAQ:CORT on TradingView ↗About the company
For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease.
In the news
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT ↗
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit ↗
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines - CORT ↗
Recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
4 filing
4 filing
144 filing
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 836,651,000Source | 840,553,000Source | 621,517,000Source | 583,430,000Source |
| Property, Plant and Equipment, NetUSD | 1,890,000Source | 2,689,000Source | 195,000Source | 633,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 120,495,000Source | 127,665,000Source | 135,551,000Source | 66,329,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 59,786,000Source | 53,976,000Source | 41,123,000Source | 31,057,000Source |
| Inventory, NetUSD | 12,868,000Source | 12,412,000Source | 7,730,000Source | 6,100,000Source |
| Assets, CurrentUSD | 485,464,000Source | 471,602,000Source | 458,636,000Source | 499,253,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 40,658,000Source | 21,880,000Source | 27,562,000Source | 16,424,000Source |
| Operating Lease, Right-of-Use AssetUSD | 4,583,000Source | 5,324,000Source | 120,000Source | 1,143,000Source |
| Other Assets, NoncurrentUSD | 5,153,000Source | 6,610,000Source | 6,541,000Source | 5,058,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 188,846,000Source | 160,964,000Source | 114,812,000Source | 81,588,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | — | — | 0Source |
| Common Stock, Value, IssuedUSD | 140,000Source | — | — | 131,000Source |
| Additional Paid in CapitalUSD | — | 832,108,000Source | 738,515,000Source | 662,342,000Source |
| Retained Earnings (Accumulated Deficit)USD | 643,387,000Source | 543,735,000Source | 402,526,000Source | 296,386,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 2,264,000Source | -217,000Source | 609,000Source | -869,000Source |
| Stockholders' Equity Attributable to ParentUSD | 647,805,000Source | 679,589,000Source | 506,705,000Source | 501,842,000Source |
| Additional Paid in Capital, Common StockUSD | 968,600,000Source | — | — | — |
| Liabilities and EquityUSD | 836,651,000Source | 840,553,000Source | 621,517,000Source | 583,430,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 166,085,000Source | 140,773,000Source | 104,505,000Source | 72,491,000Source |
| Operating Lease, Liability, CurrentUSD | 1,084,000Source | 829,000Source | 151,000Source | 1,143,000Source |
| Accounts Payable, CurrentUSD | 40,444,000Source | 15,376,000Source | 17,396,000Source | 11,976,000Source |
| Operating Lease, Liability, NoncurrentUSD | 5,023,000Source | 6,107,000Source | — | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 90,603,000Source | 90,700,000Source | 51,628,000Source | 30,799,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 1,149,000Source | 795,000Source | 577,000Source | 782,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 84,500,000Source | 61,354,000Source | 48,940,000Source | 42,442,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 5,810,000Source | 12,853,000Source | 10,066,000Source | 3,432,000Source |
| Increase (Decrease) in InventoriesUSD | 7,481,000Source | -305,000Source | -1,265,000Source | -1,199,000Source |
| Increase (Decrease) in Accounts PayableUSD | 25,068,000Source | -2,248,000Source | 5,778,000Source | 4,757,000Source |
| Deferred Income Tax Expense (Benefit)USD | -37,537,000Source | -40,191,000Source | -29,493,000Source | -33,905,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 141,996,000Source | 198,067,000Source | 127,039,000Source | 120,323,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 69,758,000Source | -177,604,000Source | 90,906,000Source | -114,327,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 211,000Source | 2,172,000Source | 139,000Source | 413,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 72,941,000Source | 22,301,000Source | 9,106,000Source | 21,665,000Source |
| Payments for Repurchase of Common StockUSD | 172,915,000Source | 15,664,000Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -220,366,000Source | -28,349,000Source | -148,723,000Source | -17,284,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -7,170,000Source | -7,886,000Source | 69,222,000Source | -11,288,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 120,495,000Source | 127,665,000Source | 135,551,000Source | 66,329,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 12,969,000Source | 60,267,000Source | 47,602,000Source | 39,747,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 1,442,000Source | — | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | — | — | 465,000Source | — |
| Income Tax Expense (Benefit)USD | -33,189,000Source | 20,284,000Source | 18,417,000Source | 14,773,000Source |
| Net Income (Loss) Attributable to ParentUSD | 99,652,000Source | 141,209,000Source | 106,140,000Source | 101,418,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 98,171,000Source | 139,733,000Source | 105,496,000Source | 101,288,000Source |
| Nonoperating Income (Expense)USD | 21,666,000Source | 24,542,000Source | 17,275,000Source | — |
| Operating Lease, ExpenseUSD | — | — | 2,400,000Source | 2,300,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | 419,793,000Source | 241,152,000Source |
| Proceeds from Stock Options ExercisedUSD | 15,869,000Source | — | — | — |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | 84,986,000Source | 61,680,000Source | 49,148,000Source | 42,722,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 761,407,000Source | 675,040,000Source | 482,375,000Source | 401,858,000Source |
| Cost of RevenueUSD | 12,977,000Source | 10,882,000Source | 6,481,000Source | 5,385,000Source |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 448,725,000Source | 280,320,000Source | 184,259,000Source | 152,848,000Source |
| Operating Income (Loss)USD | 44,797,000Source | 136,951,000Source | 107,282,000Source | 112,634,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 66,463,000Source | 161,493,000Source | 124,557,000Source | 116,191,000Source |
| Income Tax Expense (Benefit)USD | -33,189,000Source | 20,284,000Source | 18,417,000Source | 14,773,000Source |
| Net Income (Loss) Attributable to ParentUSD | 99,652,000Source | 141,209,000Source | 106,140,000Source | 101,418,000Source |
| Earnings Per Share, BasicUSD per share | 0.95Source | 1.35Source | 1.02Source | 0.95Source |
| Earnings Per Share, DilutedUSD per share | 0.82Source | 1.23Source | 0.94Source | 0.87Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 103,862,000Source | 103,232,000Source | 103,560,000Source | 106,787,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 119,987,000Source | 113,480,000Source | 111,742,000Source | 115,966,000Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | — | — | 465,000Source | — |
| Costs and ExpensesUSD | 716,610,000Source | 538,089,000Source | 375,093,000Source | 289,224,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 62,911,000Source | 159,623,000Source | 125,691,000Source | 116,871,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 98,171,000Source | 139,733,000Source | 105,496,000Source | 101,288,000Source |
| Nonoperating Income (Expense)USD | 21,666,000Source | 24,542,000Source | 17,275,000Source | — |
| Operating Lease, ExpenseUSD | — | — | 2,400,000Source | 2,300,000Source |
| Research and Development ExpenseUSD | 254,908,000Source | 246,887,000Source | 184,353,000Source | 130,991,000Source |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | 84,986,000Source | 61,680,000Source | 49,148,000Source | 42,722,000Source |
Filing attachments
d148256dex991.htm · 8-K · 2026-09-23
Exhibit 99.1 CONTACT: Investor inquiries: ir@corcept.com Media inquiries: communications@corcept.com www.corcept.com Corcept Announces Planned Leadership Transition Sean Maduck to Retire; Justin Gunn Appointed President, Endocrinology REDWOOD CITY, Calif. - September 23, 2026 - Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neu…
Read attachment ↗d159941dex991.htm · 8-K · 2026-06-17
EX-99.1 2 d159941dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 CONTACT: Investor inquiries: ir@corcept.com Media inquiries: communications@corcept.com www.corcept.com Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome REDWOOD CITY, Calif., (June 17, 2026) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrino…
Read attachment ↗d123475dex991.htm · 8-K · 2026-03-25
EX-99.1 2 d123475dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 CONTACT: Investor inquiries: ir@corcept.com Media inquiries: communications@corcept.com www.corcept.com FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli ™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer Redwood City, Calif., (March 25, 2026) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discov…
Read attachment ↗d25779dex991.htm · 8-K · 2026-02-19
EX-99.1 2 d25779dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 CONTACT: Investor inquiries: ir@corcept.com Media inquiries: communications@corcept.com www.corcept.com Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals REDWOOD CITY, Calif., (February 19, 2026) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurolog…
Read attachment ↗d96058dex991.htm · 8-K · 2026-01-22
EX-99.1 2 d96058dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 CONTACT: Investor inquiries: ir@corcept.com Media inquiries: communications@corcept.com www.corcept.com Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer Data demonstrate a 35 percent reduction in the risk of death ──────────────────────────────────────────────────────────────── Both dual primary endpoints …
Read attachment ↗d50993dex991.htm · 8-K · 2025-12-31
EX-99.1 2 d50993dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 CONTACT: Investor inquiries: ir@corcept.com Media inquiries: communications@corcept.com www.corcept.com Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism REDWOOD CITY, Calif. (Dec. 31, 2025) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinol…
Read attachment ↗